Filing Details
- Accession Number:
- 0001193125-21-036478
- Form Type:
- 13D Filing
- Publication Date:
- 2021-02-10 17:15:56
- Filed By:
- Flagship Ventures Fund V, L.p.
- Company:
- Kaleido Biosciences Inc. (NASDAQ:KLDO)
- Filing Date:
- 2021-02-10
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Flagship VentureLabs IV | 0 | 42,865 | 0 | 42,865 | 42,865 | 0.1% |
Flagship Ventures Fund IV | 0 | 1,728,309 | 0 | 1,728,309 | 1,728,309 | 4.2% |
Flagship Ventures Fund IV General Partner | 0 | 1,728,309 | 0 | 1,728,309 | 1,728,309 | 4.2% |
Flagship VentureLabs V | 0 | 2,500,000 | 0 | 2,500,000 | 2,500,000 | 6.1% |
Flagship VentureLabs V Manager | 0 | 2,500,000 | 0 | 2,500,000 | 2,500,000 | 6.1% |
Flagship Pioneering, Inc | 0 | 2,500,000 | 0 | 2,500,000 | 2,500,000 | 6.1% |
Flagship Ventures Fund V | 0 | 2,560,096 | 0 | 2,560,096 | 2,560,096 | 6.2% |
Nutritional Health Side Fund | 0 | 639,360 | 0 | 639,360 | 639,360 | 1.6% |
Nutritional Health Disruptive Innovation Fund | 0 | 6,560,523 | 0 | 6,560,523 | 6,560,523 | 16.0% |
Flagship Ventures Fund V General Partner | 0 | 9,759,979 | 0 | 9,759,979 | 9,759,979 | 23.8% |
Nutritional Health LTP Fund | 0 | 738,333 | 0 | 738,333 | 738,333 | 1.8% |
Nutritional Health LTP General Partner | 0 | 738,333 | 0 | 738,333 | 738,333 | 1.8% |
Flagship Ventures Opportunities Fund I | 0 | 2,982,639 | 0 | 2,982,639 | 2,982,639 | 7.3% |
Flagship Ventures Opportunities Fund I General Partner | 0 | 2,982,639 | 0 | 2,982,639 | 2,982,639 | 7.3% |
Flagship Ventures Fund | 0 | 216,451 | 0 | 216,451 | 216,451 | 0.5% |
Flagship Ventures | 0 | 216,451 | 0 | 216,451 | 216,451 | 0.5% |
Cadena | 0 | 1,649,999 | 0 | 1,649,999 | 1,649,999 | 4.0% |
Noubar B. Afeyan, Ph.D | 0 | 19,575,710 | 0 | 19,575,710 | 19,575,710 | 47.7% |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Kaleido Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
483347100
(CUSIP Number)
Noubar B. Afeyan, Ph.D.
Flagship Ventures
55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142
(617) 868-1888
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
February 8, 2021
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship VentureLabs IV, LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
42,865 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
42,865 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
42,865 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
0.1% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Fund IV, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
1,728,309 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
1,728,309 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,728,309 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
4.2% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Fund IV General Partner LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
AF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
1,728,309 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
1,728,309 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,728,309 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
4.2% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship VentureLabs V, LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
2,500,000 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
2,500,000 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,000 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
6.1% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship VentureLabs V Manager LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
2,500,000 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
2,500,000 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,000 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
6.1% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Pioneering, Inc. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
2,500,000 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
2,500,000 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,000 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
6.1% | |||||
14. | Type of Reporting Person (See Instructions)
CO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Fund V, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
2,560,096 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
2,560,096 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,560,096 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
6.2% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Nutritional Health Side Fund, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
639,360 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
639,360 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
639,360 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
1.6% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Nutritional Health Disruptive Innovation Fund, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
6,560,523 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
6,560,523 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
6,560,523 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
16.0% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Fund V General Partner LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
AF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
9,759,979 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
9,759,979 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
9,759,979 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
23.8% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Nutritional Health LTP Fund, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
738,333 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
738,333 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
738,333 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
1.8% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Nutritional Health LTP General Partner LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
AF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
738,333 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
738,333 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
738,333 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
1.8% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Opportunities Fund I, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
2,982,639 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
2,982,639 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,982,639 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
7.3% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Opportunities Fund I General Partner LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
AF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
2,982,639 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
2,982,639 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,982,639 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
7.3% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures Fund 2007, L.P. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
216,451 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
216,451 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
216,451 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
0.5% | |||||
14. | Type of Reporting Person (See Instructions)
PN |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Flagship Ventures 2007 General Partner LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
AF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
216,451 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
216,451 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
216,451 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
0.5% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Cadena LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
WC | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
1,649,999 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
1,649,999 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,649,999 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
4.0% | |||||
14. | Type of Reporting Person (See Instructions)
OO |
CUSIP No. 483347100 |
1. | Names of Reporting Persons.
Noubar B. Afeyan, Ph.D. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Source of Funds (See Instructions)
AF | |||||
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
6. | Citizenship or Place of Organization
United States of America |
Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
8. | Shared Voting Power
19,575,710 | |||||
9. | Sole Dispositive Power
0 | |||||
10. | Shared Dispositive Power
19,575,710 |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person
19,575,710 | |||||
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
13. | Percent of Class Represented by Amount in Row (11)
47.7% | |||||
14. | Type of Reporting Person (See Instructions)
IN |
Item 1. | Security and Issuer |
This Amendment No. 2 (this Amendment) amends and supplements the Schedule 13D (the Schedule 13D) filed by the Reporting Persons (as defined below) on March 6, 2019, as amended, with respect to the common stock, $0.001 par value per share (Common Stock), of Kaleido Biosciences, Inc. (the Issuer). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.
Item 2. | Identity and Background |
Item 2 of the Schedule 13D is hereby amended and restated as follows:
This Schedule 13D is being filed by the following persons (each a Reporting Person):
i. | Flagship VentureLabs IV, LLC, a Delaware limited liability company (VentureLabs IV). The manager of VentureLabs IV is Flagship Ventures Fund IV, L.P., a Delaware limited partnership (Flagship Fund IV and together with VentureLabs IV, the Flagship Fund IV Funds). |
ii. | Flagship Fund IV. The general partner of Flagship Fund IV is Flagship Ventures Fund IV General Partner LLC (Flagship Fund IV GP). |
iii. | Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. (Dr. Afeyan) is the sole manager of Flagship IV GP. |
iv. | Flagship VentureLabs V, LLC, a Delaware limited liability company (VentureLabs V). The manager of VentureLabs V is Flagship VentureLabs V Manager LLC, a Delaware limited liability company. (VentureLabs V Manager). |
v. | VentureLabs V Manager. The manager of VentureLabs V Manager is Flagship Pioneering, Inc. (Flagship Pioneering), a Delaware company. |
vi. | Flagship Pioneering Dr. Afeyan is the sole director of Flagship Pioneering |
vii. | Flagship Ventures Fund V, L.P., a Delaware limited partnership (Flagship Fund V). The general partner of Flagship Fund V is Flagship Ventures Fund V General Partner LLC, a Delaware limited liability company (Flagship Fund V GP). |
viii. | Nutritional Health Side Fund, L.P., a Delaware limited partnership (Nutritional Health Side Fund). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. |
ix. | Nutritional Health Disruptive Innovation Fund, L.P., a Delaware limited partnership (Nutritional Innovation Fund and together with Flagship Fund V and Nutritional Health Side Fund, the Flagship Fund V Funds). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. |
x. | Flagship Fund V GP. Dr. Afeyan is the sole manager of Flagship Fund V GP. |
xi. | Nutritional Health LTP Fund, L.P., a Delaware limited partnership (Nutritional LTP). The general partner of Nutritional LTP is Nutritional Health LTP General Partner LLC, a Delaware limited liability company (Nutritional LTP GP). |
xii. | Nutritional LTP GP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. |
xiii. | Flagship Ventures Opportunities Fund I, L.P., a Delaware limited partnership (Flagship Opportunities I).The general partner of Flagship Opportunities I is Flagship Ventures Opportunities Fund I General Partner LLC, a Delaware limited liability company (Flagship Opportunities GP). |
xiv. | Flagship Opportunities GP. Dr. Afeyan is the sole manager of Flagship Opportunities GP. |
xv. | Flagship Ventures Fund 2007, L.P., a Delaware limited partnership (Flagship Fund 2007). The general partner of Flagship Fund 2007 is Flagship Ventures 2007 General Partner LLC (Flagship Fund 2007 GP). |
xvi. | Flagship Fund 2007 GP. Dr. Afeyan is the sole manager of Flagship Fund 2007 GP. |
xvii. | Cadena LLC, a Delaware limited liability company (Cadena and together with the Flagship IV Funds, VentureLabs V, the Flagship V Funds, Nutritional LTP, Flagship Opportunities I and Flagship Fund 2007, the Flagship Funds). Dr. Afeyan is the sole manager of Cadena LLC. |
xviii. | Dr. Afeyan, a citizen of the United States of America. |
The principal business of each Reporting Person is the venture capital investment business. The principal business address of each Reporting Person is 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142.
During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
During the last five years, none of the Reporting Persons has been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 4. | Purpose of Transaction |
Item 4 is hereby amended to include the following:
On February 8, 2021, Flagship Fund IV, Flagship Opportunities I, and Nutritional LTP purchased an additional 71,666 shares, 71,667 shares, and 71,667 shares, respectively, of the Issuers Common Stock in an underwritten public offering (the February 2021 Public Offering) at a price per share of $11.50.
Item 5. | Interest in Securities of the Issuer |
Item 5(a)-(c) is hereby amended and restated as follows:
(a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 41,079,506 outstanding shares of Common Stock immediately following the February 2021 Public Offering, as reported in the Issuers prospectus supplement filed on February 5, 2021, which does not include shares of Common Stock that may be issued if the underwriters exercise their option to purchase additional shares in the offering.
VentureLabs IV and Flagship Fund IV directly hold 42,865 shares and 1,685,444 shares of Common Stock, respectively. Flagship Fund IV, as the manager of VentureLabs IV, may be deemed to beneficially own the shares directly held by VentureLabs IV. Flagship Fund IV GP, as the general partner of the Flagship Fund IV Funds, may be deemed to beneficially own the shares directly held by the Flagship Fund IV Funds.
VentureLabs V, Flagship Fund V, Nutritional Health Side Fund and Nutritional Innovation Fund directly hold 2,500,000 shares, 2,560,096 shares, 639,360 shares and 6,560,523 shares of Common Stock, respectively. VentureLabs V Manager, as the manager of VentureLabs V, and Flagship Pioneering as the manager of VentureLabs V Manager, may be deemed to beneficially own the shares directly held by VentureLabs V. Flagship Fund V GP, as the general partner of the Flagship Fund V Funds, may be deemed to beneficially own the shares directly held by the Flagship Fund V Funds.
Nutritional LTP directly holds 738,333 shares of Common Stock. Nutritional LTP GP, as the general partner of Nutritional LTP, may be deemed to beneficially own the shares directly held by Nutritional LTP.
Flagship Opportunities I directly holds 2,982,639 shares of Common Stock. Flagship Opportunities GP, as the general partner of Flagship Opportunities I, may be deemed to beneficially own the shares directly held by Flagship Opportunities I.
Flagship Fund 2007 directly holds 216,451 shares of Common Stock. Flagship Fund 2007 GP, as the general partner of Flagship Fund 2007, may be deemed to beneficially own the shares directly held by Flagship Fund 2007.
Cadena LLC directly holds 1,649,999 shares of Common Stock.
Dr. Afeyan, as the sole manager of Flagship Fund IV GP, Flagship Fund 2007 GP, Flagship Fund V GP, Nutritional LTP GP, Flagship Opportunities GP and Cadena LLC and as the sole director of Flagship Pioneering, Inc., may be deemed to beneficially own the shares directly held by the Flagship Fund IV Funds, Flagship Fund 2007, Flagship Fund V Funds, Nutritional LTP, VentureLabs V, Flagship Opportunities I and Cadena LLC.
(c) On February 8, 2021, Flagship Fund IV, Flagship Opportunities I, and Nutritional LTP purchased an additional 71,666 shares, 71,667 shares, and 71,667 shares, respectively, of the Issuers Common Stock in connection with the June 2020 Public Offering. The purchase price was $11.50 per share.
Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer |
Item 6 is hereby amended to include the following:
In connection with the February 2021 Public Offering, the Flagship funds entered into a lock-up agreement (the Lock-Up Agreement) with Morgan Stanley & Co., LLC and Piper Sandler & Co. Pursuant to the terms of the Lock-Up Agreement, the Flagship Funds have agreed, with certain exceptions, during the period ending 90 days after February 3, 2021, not to
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Issuers common stock or any securities convertible into or exercisable or exchangeable for our common stock (including without limitation, common stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition, or |
enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of our common stock or such other securities, or publicly disclose the intention to enter into any such swap or other agreement. |
The foregoing description of the Lock-Up Agreement is qualified in its entirety by reference to the full text of the Form of Lock-Up Agreement, a copy of which is filed as Exhibit 2 hereto, and is incorporated by reference into this Item 6.
Item 7. | Material to be Filed as Exhibits |
Exhibit 1 | Joint Filing Agreement (filed herewith). | |
Exhibit 2 | Lock-Up Agreement (incorporated by reference to ExhibitA-1 to Exhibit 1.1 to the Issuers Form 8-K filed on February 8, 2021). |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 10, 2021 | FLAGSHIP VENTURELABS IV, LLC | |||||||
By: | Flagship Ventures Fund IV, L.P. | |||||||
By: | Flagship Ventures Fund IV General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES FUND IV, L.P. | ||||||||
By: | Flagship Ventures Fund IV General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURELABS V, LLC | ||||||||
By: | Flagship VentureLabs V Manager LLC | |||||||
By: | Flagship Pioneering, Inc. | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Director | |||||||
FLAGSHIP VENTURELABS V MANAGER LLC | ||||||||
By: | Flagship Pioneering, Inc. | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Director |
FLAGSHIP PIONEERING, INC. | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Director | |||||||
FLAGSHIP VENTURES FUND V, L.P. | ||||||||
By: | Flagship Ventures Fund V General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
NUTRITIONAL HEALTH SIDE FUND, L.P. | ||||||||
By: | Flagship Ventures Fund V General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
NUTRITIONAL HEALTH DISRUPTIVE INNOVATION FUND, L.P. | ||||||||
By: | Flagship Ventures Fund V General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
NUTRITIONAL HEALTH LTP FUND, L.P. | ||||||||
By: | Nutritional Health LTP Fund General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager |
NUTRITIONAL HEALTH LTP FUND GENERAL PARTNER LLC | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P. | ||||||||
By: | Flagship Ventures Opportunities Fund I General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES FUND 2007, L.P. | ||||||||
By: | Flagship Ventures 2007 General Partner LLC | |||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
CADENA LLC | ||||||||
By: | /s/ Noubar B. Afeyan, Ph.D. | |||||||
Name: | Noubar B. Afeyan, Ph.D. | |||||||
Title: | Manager | |||||||
/s/ Noubar B. Afeyan, Ph.D. | ||||||||
NOUBAR B. AFEYAN, PH.D. |